By Matthew Heller ( June 19, 2013, 4:20 PM EDT) -- Dynavax Technologies Corp. investors hit the biopharmaceutical company with a putative class action Tuesday alleging it made false statements about its Heplisav vaccine for hepatitis B, causing its share price to plunge after it disclosed that regulators had safety concerns....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.